| |
The Fund
will exclusively invest in three of
the fastest growing market segments, micro and nanotechnology, information assurance and medical devices. The Fund
will source intellectual property globally, with an
emphasis on technologies created at eight renowned
regional research institutions. A documented
six-step investment process will be utilized at each
portfolio company, with a goal of achieving above
average long-term investment returns.
The Fund is managed by three seasoned executives,
Kurt F. Buseck,
Dr. Robert M. Mehalso and
Dennis V.
Pollutro. They collectively have over 75
years of successful investment and operational
experience in the three target sectors.
Research expenditures in nanotechnology have grown
exponentially over the past seven years and now
exceed $11 billion annually. Patent applications in
this field have followed a corresponding upward
trend and many of these technologies are now primed
for commercialization. Information assurance and
network security are at the forefront of concerns
for government and corporate entities. A host of new
regulations is mandating expenditures in this field.
Demographics are driving a surge in demand for
medical care across the western world. Medicine is
becoming personalized and miniaturized. Medical
devices are being fabricated with micro and nano
techniques, and disbursement of information from
remote settings in a secure manner is of paramount
importance.
The Fund will invest in each of these three areas.
The Partners envision uniquely attractive
opportunities where
two or three of these sectors are combined in one
product offering. The Fund will seek to invest $1
million as its initial funding into each portfolio
company. The Fund anticipates that it will provide
total investment of up to $3 million to each
company. A “funding gap” has developed for companies
seeking $1 million to $3 million in investment
capital. National venture firms are overseeing
larger amounts of capital, driving them to invest in
companies seeking at least $5 million to $10 million
in funding. This critical shortage of capital for
early stage companies seeking $1-3 million presents
a highly favorable investment environment for the
Fund, while the surge of capital allocations to
larger venture firms provides ample follow-on
investment for the Fund’s portfolio companies.
|
|
here
to
